ReviewMolecular cancer research : MCR2020
Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer.
Review in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- The genetic foundations of convergent traits.Nature reviews. Genetics · 2026Review
- Polyploid cancer cells surviving cisplatin reallocate central carbon sources to fuel antioxidant metabolism for survival.Molecular metabolism · 2026Article
- Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Targeting Melanoma-Associated Fibroblasts to Overcome Cancer Stem Cell-Driven Drug Resistance.Journal of the American College of Surgeons · 2026Article
- Review
- Can evolutionary therapy be applied in non-small cell lung cancer?Scientific reports · 2026Article
- Drug-tolerant persister cells reallocate carbon sources to fuel antioxidant metabolism for survival.bioRxiv : the preprint server for biology · 2026Article
- Life history enlightened therapies: cell cycle mapping to identify molecular targets to prevent hepatocellular carcinoma.Evolution, medicine, and public health · 2026Article
- Cancer, collapse, and the politics of somatic evolution.Evolution, medicine, and public health · 2026Review
- Exploring tumorigenesis as a process of phenotypic state-space exploration and selective funneling.Evolution, medicine, and public health · 2026Article
- EHBMT, a method for visualizing tumor evolution, identifies a surge in gastric cancer with hybrid epithelial-mesenchymal phenotypes due to an inflammatory microenvironment.Experimental & molecular medicine · 2025Article
- The current landscape of indole hybrids withFuture medicinal chemistry · 2025Review
- Explanations for failures in designed and evolved systems.PNAS nexus · 2025Article
- Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage.Scientific reports · 2025Article
- Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation.Frontiers in immunology · 2025Review
- Nrf1 acts as a highly-conserved determinon for maintaining robust redox homeostasis in the eco-evo-devo process of life histories.Cell stress · 2025Review
- Eco-evolutionary dynamics of structured populations in periodically fluctuating environments: a G function approach.Theory in biosciences = Theorie in den Biowissenschaften · 2024Article
- A method for in silico exploration of potential glioblastoma multiforme attractors using single-cell RNA sequencing.Scientific reports · 2024Article
- Human and bats genome robustness under COSMIC mutational signatures.bioRxiv : the preprint server for biology · 2024Article
- Modeling stress-induced responses: plasticity in continuous state space and gradual clonal evolution.Theory in biosciences = Theorie in den Biowissenschaften · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advances in curative treatment to remove the primary tumor have increased survival of localized cancers for most solid tumor types, yet cancers that have spread are typically incurable and account for >90% of cancer-related deaths. Metastatic disease remains incurable because, somehow, tumors evolve resistance to all known compounds, including therapies. In all of these incurable patients,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.